New oral anticoagulants in nonvalvular atrial fibrillation

Author:

Apostolović SvetlanaORCID,Stanojević DraganaORCID,Kostić Tomislav

Abstract

Atrial fibrillation (AF) is the most common arrhythmia in clinical practice and its incidence is 1-2% of the world's population. Atrial fibrillation is associated with an increased risk of morbidity and mortality, primarily due to an increased risk of stroke that is five times higher than in the general population. Therefore, life-long anticoagulant therapy is indicated in patients with atrial fibrillation in the prevention of stroke when CHA2DS2-VASc [congestive heart failure, hypertension, age > 75 years, diabetes mellitus, stroke, vascular disease, age 65-74 years, gender (female)] score > 2 in men and > 3 in women. For last ten years, anticoagulant therapy involved the use of vitamin K antagonists, primarily warfarin. Until the appearance of non-vitamin K oral anticoagulants (NOACs), that do not require routine efficacy monitoring and have more favorable pharmacological profile, warfarin use is significantly reduced in non-valvular AF. By the year 2017. the percentage of patients on NOAC-s exceeded the number of those on warfarin worldwide. Four NOAC-s are approved for use in patients with AF of nonvalvular origin in Europe: apixaban, dabigatran, edoxaban and rivaroxaban. Evidence from phase III studies suggests that NOAC-s are more effective and safer than warfarin. The most prescribed NOAC in almost all "real life" studies from the USA was rivaroxaban. For rivaroxaban "real life data" such as the XANTUS study show that the incidence of stroke and major bleeding is low (0.7 and 2.1 events per 100 patients / year). The efficacy of rivaroxaban in nonvalvular AF was first demonstrated in the ROCKET-AF large, multicenter, randomized, double-blind study in 14,264 patients. Rivaroxaban was non-inferior to warfarin in the prevention of ischemic stroke and systemic embolism. The overall percentages of major and clinically relevant non-major haemorrhages did not differ between rivaroxaban and warfarin, but there were fewer intracranial or fatal haemorrhages in the rivaroxaban group (0,5% vs 0,7% per year, HR 0,67, 95% CI 0,47-0,93, p = 0,02).

Publisher

Centre for Evaluation in Education and Science (CEON/CEES)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3